Skip to content
Study details
Enrolling now

A Study of ZT-01 on Nighttime Hypoglycemia in Type 1 Diabetes

Zucara Therapeutics Inc.
NCT IDNCT05762107ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

186

Study length

about 3.8 years

Ages

18–75

Locations

26 sites in CA, FL, GA +11

About this study

This trial is testing a treatment called ZT-01 to see if it helps prevent nighttime low blood sugar (hypoglycemia) in adults with type 1 diabetes. Participants will use a continuous glucose monitor and take ZT-01 at different doses, or a placebo, for two periods of four weeks each. The goal is to determine if ZT-01 lowers the number of hypos happening at night and what its effects are on blood sugar levels.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take ZT-01, 15 mg
  • 3.Take ZT-01, 22 mg
  • +1 more
PhasePhase 2

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low6%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: Incidence and severity of adverse events (AEs)

Body systems

Endocrinology